Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone

Daniela Manno; Philip Ayieko; David Ishola; Muhammed O. Afolabi; Baimba Rogers; Frank Baiden; Alimamy Serry-Bangura; Osman M. Bah; Brian Köhn; Ibrahim Swaray; Kwabena Owusu-Kyei; Godfrey T. Otieno; Dickens Kowuor; Daniel Tindanbil; Elizabeth Smout; Cynthia Robinson; Babajide Keshinro; Julie Foster; Katherine Gallagher; Brett Lowe; Macaya Douoguih; Bailah Leigh; Brian Greenwood; Deborah Watson-Jones

doi:10.3201/eid2803.211496

Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone

Daniela Manno
, Philip Ayieko
, David Ishola
, Muhammed O. Afolabi
, Baimba Rogers
, Frank Baiden
, Alimamy Serry-Bangura
, Osman M. Bah
, Brian Köhn
, Ibrahim Swaray
, Kwabena Owusu-Kyei
, Godfrey T. Otieno
, Dickens Kowuor
, Daniel Tindanbil
, Elizabeth Smout
, Cynthia Robinson
, Babajide Keshinro
, Julie Foster
, Katherine Gallagher
, Brett Lowe

Macaya Douoguih, Bailah Leigh, Brian Greenwood, Deborah Watson-Jones

London School of Hygiene and Tropical Medicine

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Ebola virus (EBOV) antibodies have been found in populations that have never experienced documented Ebola outbreaks and in persons who reported no history of Ebola virus disease (EVD) (1). The clinical significance of these findings is unknown. We conducted a cross-sectional study in healthy adults and children from a population affected by the 2014–2016 EVD outbreak in Sierra Leone and explored the association of antibody seropositivity and concentration with potential risk factors for EBOV infection.

Original language	English
Pages (from-to)	734-738
Number of pages	5
Journal	Emerging Infectious Diseases
Volume	28
Issue number	3
DOIs	https://doi.org/10.3201/eid2803.211496
Publication status	Published - 15 Feb 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3201/eid2803.211496Licence: CC BY

4Final published version, 0.99 MBLicence: CC BY

Cite this

Manno, D., Ayieko, P., Ishola, D., Afolabi, M. O., Rogers, B., Baiden, F., Serry-Bangura, A., Bah, O. M., Köhn, B., Swaray, I., Owusu-Kyei, K., Otieno, G. T., Kowuor, D., Tindanbil, D., Smout, E., Robinson, C., Keshinro, B., Foster, J., Gallagher, K., ... Watson-Jones, D. (2022). Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone. Emerging Infectious Diseases, 28(3), 734-738. https://doi.org/10.3201/eid2803.211496

@article{5596c8c568e242119a10a42b25387d49,

title = "Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone",

abstract = "Ebola virus (EBOV) antibodies have been found in populations that have never experienced documented Ebola outbreaks and in persons who reported no history of Ebola virus disease (EVD) (1). The clinical significance of these findings is unknown. We conducted a cross-sectional study in healthy adults and children from a population affected by the 2014–2016 EVD outbreak in Sierra Leone and explored the association of antibody seropositivity and concentration with potential risk factors for EBOV infection.",

author = "Daniela Manno and Philip Ayieko and David Ishola and Afolabi, \{Muhammed O.\} and Baimba Rogers and Frank Baiden and Alimamy Serry-Bangura and Bah, \{Osman M.\} and Brian K{\"o}hn and Ibrahim Swaray and Kwabena Owusu-Kyei and Otieno, \{Godfrey T.\} and Dickens Kowuor and Daniel Tindanbil and Elizabeth Smout and Cynthia Robinson and Babajide Keshinro and Julie Foster and Katherine Gallagher and Brett Lowe and Macaya Douoguih and Bailah Leigh and Brian Greenwood and Deborah Watson-Jones",

year = "2022",

month = feb,

day = "15",

doi = "10.3201/eid2803.211496",

language = "English",

volume = "28",

pages = "734--738",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "3",

}

Manno, D, Ayieko, P, Ishola, D, Afolabi, MO, Rogers, B, Baiden, F, Serry-Bangura, A, Bah, OM, Köhn, B, Swaray, I, Owusu-Kyei, K, Otieno, GT, Kowuor, D, Tindanbil, D, Smout, E, Robinson, C, Keshinro, B, Foster, J, Gallagher, K, Lowe, B, Douoguih, M, Leigh, B, Greenwood, B & Watson-Jones, D 2022, 'Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone', Emerging Infectious Diseases, vol. 28, no. 3, pp. 734-738. https://doi.org/10.3201/eid2803.211496

TY - JOUR

T1 - Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone

AU - Manno, Daniela

AU - Ayieko, Philip

AU - Ishola, David

AU - Afolabi, Muhammed O.

AU - Rogers, Baimba

AU - Baiden, Frank

AU - Serry-Bangura, Alimamy

AU - Bah, Osman M.

AU - Köhn, Brian

AU - Swaray, Ibrahim

AU - Owusu-Kyei, Kwabena

AU - Otieno, Godfrey T.

AU - Kowuor, Dickens

AU - Tindanbil, Daniel

AU - Smout, Elizabeth

AU - Robinson, Cynthia

AU - Keshinro, Babajide

AU - Foster, Julie

AU - Gallagher, Katherine

AU - Lowe, Brett

AU - Douoguih, Macaya

AU - Leigh, Bailah

AU - Greenwood, Brian

AU - Watson-Jones, Deborah

PY - 2022/2/15

Y1 - 2022/2/15

N2 - Ebola virus (EBOV) antibodies have been found in populations that have never experienced documented Ebola outbreaks and in persons who reported no history of Ebola virus disease (EVD) (1). The clinical significance of these findings is unknown. We conducted a cross-sectional study in healthy adults and children from a population affected by the 2014–2016 EVD outbreak in Sierra Leone and explored the association of antibody seropositivity and concentration with potential risk factors for EBOV infection.

AB - Ebola virus (EBOV) antibodies have been found in populations that have never experienced documented Ebola outbreaks and in persons who reported no history of Ebola virus disease (EVD) (1). The clinical significance of these findings is unknown. We conducted a cross-sectional study in healthy adults and children from a population affected by the 2014–2016 EVD outbreak in Sierra Leone and explored the association of antibody seropositivity and concentration with potential risk factors for EBOV infection.

U2 - 10.3201/eid2803.211496

DO - 10.3201/eid2803.211496

M3 - Article

SN - 1080-6040

VL - 28

SP - 734

EP - 738

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 3

ER -

Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this